Analystreport

Sangamo Therapeutics (NASDAQ:SGMO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.

Sangamo Therapeutics, Inc.  (SGMO) 
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sangamo.com